Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Apr 7:13:883967.
doi: 10.3389/fimmu.2022.883967. eCollection 2022.

Case Report: Diagnostic and Therapeutic Challenges in Severe Mechanobullous Epidermolysis Bullosa Acquisita

Affiliations
Case Reports

Case Report: Diagnostic and Therapeutic Challenges in Severe Mechanobullous Epidermolysis Bullosa Acquisita

Franziska Schauer et al. Front Immunol. .

Abstract

Collagen VII is the main constituent of the anchoring fibrils, important adhesive structures that attach the epidermis to the dermal extracellular matrix. Two disorders are caused by dysfunction of collagen VII, both characterized by skin and mucosa fragility, epidermolysis bullosa acquisita (EBA) and dystrophic epidermolysis bullosa (DEB). EBA and DEB share high clinical similarities with significant difference in patients' age of onset and pathogenesis. Our patients presented with severe and recalcitrant mechanobullous EBA with characteristic DIF, IIF and ELISA diagnostics. But in both women recessive COL7A1 variants were also found, in a monoallelic state. Collagen VII from EBA keratinocytes of our cases was significantly more vulnerable to proteolytic degradation than control keratinocytes, hinting that the heterozygous pathogenic variants were sufficient to destabilize the molecule in vitro. Thus, even if the amount and functionality of mutant and normal type VII collagen polypeptides is sufficient to assure dermal-epidermal adhesion in healthy individuals, the functionally-impaired proteins are probably more prone to development of autoantibodies against them. Our work suggests that testing for COL7A1 genetic variants should be considered in patients with EBA, which either have a patient history hinting towards underlying dystrophic epidermolysis bullosa or pose therapeutic challenges.

Keywords: COL7A1; collagen VII; immunoglobulin; rituximab; skin blistering; skin fragility.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Clinical manifestations in both cases. (A) Clinical presentation of case 1 with blisters, erosions and scaring of her back, tongue, scarring alopecia, chest and nail dystrophy/loss presented at her left foot. (B) Case 2 shows similar lesions on her skin, mucous membranes (mouth and esophagus), as well as progressive scarring and milia on the backs of the hands. The finger nails are intact.
Figure 2
Figure 2
Results of the diagnostic assessment. (A) Direct immunofluorescence with linear IgG along the DEJZ and (B) immunofluorescence mapping of patient 1 and 2 showing regular staining of collagen VII compared to healthy control. Collagen VII of patient 1 stains at dermal and epidermal side within the blister, reminiscent of an older blister. Collagen VII of patient 2 shows wider depositions at DEJZ and interruptions due to microblistering. (C) Immunoblot of the trypsine-digested collagen VII shows degradation at lower temperatures in the patients’ keratinocyte lysates, as graphically depicted in (D). * equals p: 0,0118 as tested with 2-WAY ANOVA.

Similar articles

Cited by

References

    1. Chen M, Marinkovich MP, Veis A, Cai X, Rao CN, O’Toole EA. Interactions of the Amino-Terminal Noncollagenous (NC1) Domain of Type VII Collagen With Extracellular Matrix Components. J Biol Chem (1997) 272(23):14516–22. doi: 10.1074/jbc.272.23.14516 - DOI - PubMed
    1. Nyström A, Bruckner-Tuderman L, Kiritsi D. Dystrophic Epidermolysis Bullosa: Secondary Disease Mechanisms and Disease Modifiers. Front Genet (2021) 12:1737. doi: 10.3389/fgene.2021.737272 - DOI - PMC - PubMed
    1. Koga H, Prost-Squarcioni C, Iwata H, Jonkman MF, Ludwig RJ, Bieber K. Epidermolysis Bullosa Acquisita: The 2019 Update. Front Med (2019) 5. doi: 10.3389/fmed.2018.00362 - DOI - PMC - PubMed
    1. Has C, Bauer JW, Bodemer C, Bolling MC, Bruckner-Tuderman L, Diem A. Consensus Reclassification of Inherited Epidermolysis Bullosa and Other Disorders With Skin Fragility. Br J Dermatol (2020) 183(4):614–27. doi: 10.1111/bjd.18921 - DOI - PubMed
    1. Ludwig RJ. Clinical Presentation, Pathogenesis, Diagnosis, and Treatment of Epidermolysis Bullosa Acquisita. ISRN Dermatol (2013) 2013:812029. Pasmatzi E, Janniger CK, Nagore E, Kaneko F, Herausgeber. doi: 10.1155/2013/812029 - DOI - PMC - PubMed

Publication types

LinkOut - more resources